Navigation Links
Encouraging results in pancreatic cancer research

Researchers at SUNY Downstate Medical Center and the Brooklyn VA Hospital have found that when a human protein, PNC-28, is administered to pancreatic tumor cells in animals, the tumors are destroyed. The research was reported in the October 1st edition of the International Journal of Cancer.

Matthew R. Pincus, MD, PhD, professor of pathology at SUNY Downstate and chairman of pathology and laboratory medicine at the Brooklyn VA, said, "The results are very encouraging. PNC-28 may be an effective agent in treating cancers, especially if delivered directly to the tumor."

PNC-28 is a p53 peptide, a naturally occurring human protein known to suppress tumor growth. The researchers previously found that PNC-28 induces death of a variety of human tumor cell lines, including a pancreatic cancer cell line, while not harming healthy cells.

The research team has now given PNC-28 to laboratory animals to test its ability to block the growth of pancreatic cancer cells. When administered over a two-week period in the peritoneal cavities of mice containing simultaneously transplanted tumors, PNC-28 caused complete destruction of these tumors.

When delivered concurrently with tumor implantation, PNC-28 completely blocked tumor growth during the two-week period of administration and two weeks post-treatment, followed by weak tumor growth that leveled off at low tumor sizes.

In addition, according to Josef Michl, MD, associate professor of pathology at SUNY Downstate, "When administered from a site distant from the tumor, PNC-28 still caused a decrease in tumor size. This tumor growth was significantly slower than growth in the presence of a control peptide."

Dr. Pincus added that this peptide and its parent peptide, called PNC-27, are lethal to a wide variety of human cancer cells, besides pancreatic cancer, including colon, breast, cervical and bone (osteogenic sarcoma) cancers. These peptides kill cancer cells that do not even contain native p53 protein and therefore appear to have a wide applicability in treating a variety of human cancers.
'"/>

Source:SUNY Downstate Medical Center


Related biology news :

1. Gene vaccine for Alzheimers disease shows promising results
2. Roche clinical trial registry and results database launched
3. Diabetic nerve therapy shows striking results
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. New results validating Pall prion reduction filter disclosed at ISBT Congress
6. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
7. Combination therapy shows promising results in patients with advanced lung cancer
8. Vaccine for brain tumors shows promising results
9. Artificial cornea offers better results for infants, some blind patients
10. The eyes have it -- Autism research yields surprising results
11. UCSF brain tumor vaccine trial shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... 2017 , ... Vortex Biosciences , provider of circulating tumor cell (CTC) ... cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication ...
(Date:5/23/2017)... ... ... Cambridge Semantics , the leading provider of Big Data management and analytics ... in Boston May 23-25 with a featured speaker and solution demos of its ... also a finalist for the Best of Show award. , James LaPointe, Managing Director ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... it is exhibiting in booth B2 at the Association for Pathology Informatics ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... Academic researchers with technologies ripe for commercialization, and who are affiliated with ... are encouraged to submit proposals. QED, now in its tenth round, is the ...
Breaking Biology Technology: